Chai M, Zhang CY, Chen S, Xu DH. Application of autophagy in mesenchymal stem cells. World J Stem Cells 2024; 16(12): 990-1001 [DOI: 10.4252/wjsc.v16.i12.990]
Corresponding Author of This Article
Da-Hai Xu, MD, Department of Emergency Medicine, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130000, Jilin Province, China. xudahai0319@jlu.edu.cn
Research Domain of This Article
Cell Biology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Dec 26, 2024; 16(12): 990-1001 Published online Dec 26, 2024. doi: 10.4252/wjsc.v16.i12.990
Application of autophagy in mesenchymal stem cells
Min Chai, Chun-Yan Zhang, Shuai Chen, Da-Hai Xu
Min Chai, Da-Hai Xu, Department of Emergency Medicine, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China
Chun-Yan Zhang, Department of Rehabilitation Medicine, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China
Shuai Chen, Department of Emergency Surgery, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China
Co-first authors: Min Chai and Chun-Yan Zhang.
Co-corresponding authors: Shuai Chen and Da-Hai Xu.
Author contributions: Chai M and Zhang CY wrote and edited the manuscript, and they contributed equally to this manuscript as co-first authors; Chen S and Xu DH revised and supervised the manuscript, and they contributed equally to this manuscript as co-corresponding authors. All authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Da-Hai Xu, MD, Department of Emergency Medicine, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130000, Jilin Province, China. xudahai0319@jlu.edu.cn
Received: September 5, 2024 Revised: November 5, 2024 Accepted: December 2, 2024 Published online: December 26, 2024 Processing time: 98 Days and 19.6 Hours
Abstract
In this editorial, we have taken an in-depth look at the article published by Wan et al. The study showed that preconditioning mesenchymal stem cells (MSCs) protected them against programmed cell death, and increased their survival rate and therapeutic potential. Autophagy, a type of programmed cell death, is a major intracellular degradation and recycling pathway that is crucial for maintaining cellular homeostasis, self-renewal, and pluripotency. We have explored the relationship between autophagy and MSCs to determine the role of autophagy in the therapeutic applications of MSCs.
Core Tip: Reducing the programmed death of pre-conditioned bone marrow-derived mesenchymal stem cells can significantly enhance their engraftment, survival, and differentiation potential, and modulate the immune microenvironment of the recipient tissue. Autophagy, an important complementary pathway of programmed cell death, plays a crucial role in cellular homeostasis, self-renewal, and functional regulation. Regulating autophagy in mesenchymal stem cells provides a new perspective and strategy for stem cell therapy.
